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Active immunotherapy is an interesting field from the industry’s perspective and in
the last years, regulatory agencies and the medical community have showed renewed
expectations and interest in cancer vaccines. The development of new immune therapies
offers many challenges, and this is reflected in the small number of phase III trials
showing clear benefits. Traditional concepts applied in clinical trials for the development of
chemotherapeutic agents may be inadequate for immunotherapies and a new paradigm is
emerging. It is possible that organized efforts and funding will accelerate the development
of therapeutically effective cancer vaccines. This article reviews the attributes of cancer
vaccines which make them attractive from the industry’s perspective, and focuses
especially in the characteristics of Racotumomab, an anti-idiotype antibody vaccine.
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There are different immunotherapeutic approaches in cancer,
including passive and active immunotherapy, adoptive T cell
transfer, and non-specific immunotherapy, amongst others.
Active immunotherapy is an interesting field because vaccines
usually have a favorable side effect profile and are well-tolerated
and can be used in combination with other therapies.
However, the development of these new immune therapies
offers many challenges, and this is reflected in the small number
of phase III trials showing clear benefits. Immune response may
not always translate into clinical benefit, and for solid tumors,
traditional criteria for evaluation of tumor response may not be
appropriate or relevant (Tuma, 2006; Hoos et al., 2007; Schlom
et al., 2007).
In the last years, the regulatory agencies and the medical
community have increased their expectations regarding these
therapeutic strategies. The FDA released in October 2011a guid-
ance document for the industry addressing the challenges and
particular issues with the development of cancer vaccines such as
monitoring for immune response, disease progression/recurrence
immediately or shortly after the start of the vaccine, delayed
effects of the vaccines when evaluating time to event end-
points, etc (Guidance for Industry, 2011). This shows that in
the development phases of vaccines and immunotherapies, some
of the traditional concepts applied in oncology clinical trials for
chemotherapeutic agents are at least controversial or inappropri-
ate and a new paradigm is emerging for immunotherapies.
The NCI recently recognized the untapped potential of ther-
apeutic cancer vaccines and set a pilot project for identification
and prioritization of cancer antigens (Cheever et al., 2009). There
is increasing interest in the cancer vaccine field, and it is possible
that organized efforts and funding will accelerate the develop-
ment of therapeutically effective cancer vaccines.
The successful development of a vaccine for cancer treatment
is influenced by several factors. Some of them are related to
the product, type of tumor, expression of the target, and also to
the patient characteristics, such as performance status or stage
of the disease, play an important role.
An anti-idiotype monoclonal antibody (mAb) is the mirror
image of the original antibody formed against specific surface
antigens. Thus, anti-idiotype antibodies can act as antigens,
inducing a response against the original antigen.
Racotumomab is an anti-idiotype antibody used as a ther-
apeutic vaccine. Although it is as mAb, it is administered in
small amounts, intradermally, and acts as an active specific
immunotherapeutic agent.
Racotumomab was formerly known as 1E10 anti-idiotype vac-
cine and is a good example of a candidate for development
because it holds many positive characteristics:
• It has a well-defined antigen, expressed only in tumor cells:
N-glycolil-GM3 is the target of this vaccine. It is a ganglio-
side which normally does not express on the surface of human
cells, but appears on the surface of tumor cells (Irie et al., 1998;
Muchmore et al., 1998). The differential expression of the tar-
get makes immune cross reactions unlikely, hence preserving
normal cells and reducing the risks of toxicity and side effects.
• The target is expressed in several tumor types: it has been
shown that several tumors express N-glycolil-GM3, such as
non-small cell lung cancer (van Cruijsen et al., 2009), breast
cancer (Vázquez et al., 1995; Moreno et al., 1998), melanoma
(Alfonso et al., 2002), and several pediatric tumors of neu-
roectodermal origin (Scursoni et al., 2011, 2012). From the
industry’s perspective this is interesting because it allows a
broad range of potential indications. Particularly in the case
of non-small cell lung cancer, the expression of the target is
greater than 70% (van Cruijsen et al., 2009). This provides
two additional advantages: (1) the potential for combination
of Racotumomab with other therapies used in more selected
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FIGURE 1 | Racotumomab—mechanism of action of an anti-idiotype antibody.
FIGURE 2 | Immune response to vaccination with Racotumomab.
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patient populations (patient with specific mutations or his-
tological types) without the need of prior evaluation of the
presence of the target in the tumor and (2) even if the
detection of the target ganglioside (N-glycolil-GM3) were
needed, the fact that it is an immunohystochemical evaluation,
makes it technically easy to perform, of low cost and widely
accessible.
• It has an innovative mechanism of action (Figure 1): anti-
idiotype antibodies are a useful strategy to elicit an immune
response toward a ganglioside, which is a scarcely immuno-
genic molecule in itself.
• It is highly immunogenic (Figure 2) and shows clinical benefit:
Racotumomab is a monoclonal antibody, but is used as a vac-
cine. Only a small quantity of Racotumomab (1 mg) is needed
per dose. It has been shown that Racotumomab is able to elicit
a strong humoral and cellular immune response (Alfonso et al.,
2002; Díaz et al., 2003; Guthmann et al., 2004, 2006; Hernández
et al., 2008, 2011) and that this response has a positive impact
in patient survival (Guthmann et al., 2004; Alfonso et al., 2007;
Neninger et al., 2007). In a proof of concept trial, patients with
NSCLC treated with Racotumomab had a longer overall sur-
vival in comparison to a placebo group (final results submitted
for publication).
• It can be used in a broad target population: despite the fact
that more than 65% of all malignancies and more than 70%
of the deaths associated to cancer occur in patients beyond 65
years old (Lynn et al., 2003), elderly patients continue to be
underrepresented in clinical trials. The incidence of cancer is
10 times larger and death rate is 16 times larger in this group
than patients below 65 years of age (Lynn et al., 2003). When
the treatments evaluated in younger patient populations are
approved and then used in the clinical setting and in elderly
patients frequently the results obtained are not the same. Due
to comorbidities and polimedication the risk of side effects,
toxicity and complications is increased, and the tolerance to
onco-specific treatments is reduced. Several studies have shown
that patients more than 65 years old tend to have a greater
risk of bone marrow depletion, neutropenia, infections, and
neurotoxicity with the use of chemotherapy (Balducci, 2001,
2003; Balducci and Repetto, 2004; Belani, 2005; Gridelli, 2008).
Cancer treatment in pediatric population presents a similar
challenge. In addition, traditional cancer agents have impact
in developing organs and systems and are likely to produce
irreversible, negative changes.
• Well-tolerated and safe products such as Racotumomab
continue to be very much needed in these specific patient
populations. This is also very important for diseases with
late diagnosis and no chance of cure, because in this context
patients and their families tend to recur to alternative therapies
which may be costly, ineffective and unsafe.
• The schedule of vaccination is comfortable and simple: it con-
sists of five intradermal doses (1 every 2 weeks) followed by
subsequent monthly intradermal doses.
• The administration of the vaccine is quick and easy: the route
of administration of Racotumomab and the fact that this prod-
uct does not require the safety precautions that are needed
when manipulating chemotherapeutic agents, nor costly pro-
cessing or time consuming infusions makes this treatment
interesting, since it can be delivered by a nurse at home, at the
pharmacy or at the clinic. Although in the clinical trials it is
recommended that the patients remain 1 h in observation after
the first 2 doses, no threatening immediate reactions have been
observed so far in more than 700 treated patients and no fur-
ther surveillance is required if the vaccine was well-tolerated.
All these factors favor patient compliance to therapy and have
an impact on quality of life.
• Good tolerance and feasibility of combination with stan-
dard therapies: preservation of the patient’s quality of liv-
ing is extremely important, especially when there are no
chances of cure and palliative therapies are the only option.
Racotumomab is mostly associated with mild to moderate
injection-site reactions (local erithema, induration, and pain),
which disappear within 24–48 h. Systemic reactions, such as
flu like symptoms and chills are less frequent, reversible, and
self-limited. A favorable safety profile allows administration
of monthly booster doses during a long period of time to
maintain the immune response beyond disease progression,
possibilities of treatment combinations with a broad range
of standard therapies (radiotherapy, chemotherapies, etc.,)
and use in special populations such as elderly and pediatric
patients. Especially in NSCLC Racotumomab could play a role
in maintenance therapy, with an acceptable and easy admin-
istration schedule and a favorable safety profile, alone or in
combination with other agents.
In summary, Racotumomab is a well-tolerated, immunogenic
cancer vaccine which has shown to prolong survival in NSCLC
and is currently being evaluated in a multinational, phase III trial.
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